vs
MAXIMUS, INC.（MMS）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
MAXIMUS, INC.的季度营收约是Revvity的1.7倍（$1.3B vs $772.1M），Revvity净利率更高（12.7% vs 7.0%，领先5.8%），Revvity同比增速更快（5.9% vs -4.1%），Revvity自由现金流更多（$161.8M vs $-250.7M），过去两年Revvity的营收复合增速更高（9.0% vs -0.1%）
MAXIMUS是美国一家政府服务企业，业务覆盖美国、加拿大、英国等国家，为医疗补助、联邦医疗保险、医改、就业帮扶、学生贷款服务等各类政府项目提供行政及配套服务。公司总部位于弗吉尼亚州泰森斯，现有员工3.96万名，2024财年营收达53亿美元。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MMS vs RVTY — 直观对比
营收规模更大
MMS
是对方的1.7倍
$772.1M
营收增速更快
RVTY
高出10.0%
-4.1%
净利率更高
RVTY
高出5.8%
7.0%
自由现金流更多
RVTY
多$412.5M
$-250.7M
两年增速更快
RVTY
近两年复合增速
-0.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $772.1M |
| 净利润 | $93.9M | $98.4M |
| 毛利率 | 23.7% | — |
| 营业利润率 | 10.9% | 14.5% |
| 净利率 | 7.0% | 12.7% |
| 营收同比 | -4.1% | 5.9% |
| 净利润同比 | 128.0% | 3.9% |
| 每股收益（稀释后） | $1.70 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MMSRVTY
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.3B | $698.9M | ||
| Q2 25 | $1.3B | $720.3M | ||
| Q1 25 | $1.4B | $664.8M | ||
| Q4 24 | $1.4B | $729.4M | ||
| Q3 24 | $1.3B | $684.0M | ||
| Q2 24 | $1.3B | $691.7M | ||
| Q1 24 | $1.3B | $649.9M |
净利润MMSRVTY
| Q4 25 | $93.9M | $98.4M | ||
| Q3 25 | $75.3M | $46.7M | ||
| Q2 25 | $106.0M | $53.9M | ||
| Q1 25 | $96.6M | $42.2M | ||
| Q4 24 | $41.2M | $94.6M | ||
| Q3 24 | $72.5M | $94.4M | ||
| Q2 24 | $89.8M | $55.4M | ||
| Q1 24 | $80.5M | $26.0M |
毛利率MMSRVTY
| Q4 25 | 23.7% | — | ||
| Q3 25 | 25.3% | 53.6% | ||
| Q2 25 | 26.7% | 54.5% | ||
| Q1 25 | 24.9% | 56.5% | ||
| Q4 24 | 21.5% | — | ||
| Q3 24 | 22.9% | 56.3% | ||
| Q2 24 | 25.3% | 55.7% | ||
| Q1 24 | 23.6% | 54.6% |
营业利润率MMSRVTY
| Q4 25 | 10.9% | 14.5% | ||
| Q3 25 | 9.3% | 11.7% | ||
| Q2 25 | 12.3% | 12.6% | ||
| Q1 25 | 11.2% | 10.9% | ||
| Q4 24 | 6.2% | 16.3% | ||
| Q3 24 | 8.5% | 14.3% | ||
| Q2 24 | 10.8% | 12.4% | ||
| Q1 24 | 9.5% | 6.8% |
净利率MMSRVTY
| Q4 25 | 7.0% | 12.7% | ||
| Q3 25 | 5.7% | 6.7% | ||
| Q2 25 | 7.9% | 7.5% | ||
| Q1 25 | 7.1% | 6.4% | ||
| Q4 24 | 2.9% | 13.0% | ||
| Q3 24 | 5.5% | 13.8% | ||
| Q2 24 | 6.8% | 8.0% | ||
| Q1 24 | 6.0% | 4.0% |
每股收益（稀释后）MMSRVTY
| Q4 25 | $1.70 | $0.86 | ||
| Q3 25 | $1.27 | $0.40 | ||
| Q2 25 | $1.86 | $0.46 | ||
| Q1 25 | $1.69 | $0.35 | ||
| Q4 24 | $0.69 | $0.77 | ||
| Q3 24 | $1.18 | $0.77 | ||
| Q2 24 | $1.46 | $0.45 | ||
| Q1 24 | $1.31 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $137.6M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.7B | $7.3B |
| 总资产 | $4.2B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MMSRVTY
| Q4 25 | $137.6M | $919.9M | ||
| Q3 25 | $222.4M | $931.4M | ||
| Q2 25 | $59.8M | $991.8M | ||
| Q1 25 | $108.1M | $1.1B | ||
| Q4 24 | $72.7M | $1.2B | ||
| Q3 24 | $183.1M | $1.2B | ||
| Q2 24 | $102.8M | $2.0B | ||
| Q1 24 | $77.4M | $1.7B |
股东权益MMSRVTY
| Q4 25 | $1.7B | $7.3B | ||
| Q3 25 | $1.7B | $7.4B | ||
| Q2 25 | $1.8B | $7.6B | ||
| Q1 25 | $1.7B | $7.6B | ||
| Q4 24 | $1.6B | $7.7B | ||
| Q3 24 | $1.8B | $7.9B | ||
| Q2 24 | $1.8B | $7.9B | ||
| Q1 24 | $1.8B | $7.8B |
总资产MMSRVTY
| Q4 25 | $4.2B | $12.2B | ||
| Q3 25 | $4.1B | $12.1B | ||
| Q2 25 | $4.5B | $12.4B | ||
| Q1 25 | $4.2B | $12.4B | ||
| Q4 24 | $4.1B | $12.4B | ||
| Q3 24 | $4.1B | $12.8B | ||
| Q2 24 | $4.0B | $13.4B | ||
| Q1 24 | $4.0B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-244.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-250.7M | $161.8M |
| 自由现金流率自由现金流/营收 | -18.6% | 21.0% |
| 资本支出强度资本支出/营收 | 0.5% | 2.6% |
| 现金转化率经营现金流/净利润 | -2.60× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $218.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流MMSRVTY
| Q4 25 | $-244.4M | $182.0M | ||
| Q3 25 | $649.4M | $138.5M | ||
| Q2 25 | $-182.7M | $134.3M | ||
| Q1 25 | $42.7M | $128.2M | ||
| Q4 24 | $-80.0M | $174.2M | ||
| Q3 24 | $163.8M | $147.9M | ||
| Q2 24 | $199.3M | $158.6M | ||
| Q1 24 | $130.5M | $147.6M |
自由现金流MMSRVTY
| Q4 25 | $-250.7M | $161.8M | ||
| Q3 25 | $641.8M | $120.0M | ||
| Q2 25 | $-198.2M | $115.5M | ||
| Q1 25 | $25.5M | $112.2M | ||
| Q4 24 | $-103.0M | $149.8M | ||
| Q3 24 | $131.9M | $125.6M | ||
| Q2 24 | $164.6M | $136.6M | ||
| Q1 24 | $105.2M | $129.7M |
自由现金流率MMSRVTY
| Q4 25 | -18.6% | 21.0% | ||
| Q3 25 | 48.7% | 17.2% | ||
| Q2 25 | -14.7% | 16.0% | ||
| Q1 25 | 1.9% | 16.9% | ||
| Q4 24 | -7.3% | 20.5% | ||
| Q3 24 | 10.0% | 18.4% | ||
| Q2 24 | 12.5% | 19.7% | ||
| Q1 24 | 7.8% | 20.0% |
资本支出强度MMSRVTY
| Q4 25 | 0.5% | 2.6% | ||
| Q3 25 | 0.6% | 2.6% | ||
| Q2 25 | 1.1% | 2.6% | ||
| Q1 25 | 1.3% | 2.4% | ||
| Q4 24 | 1.6% | 3.4% | ||
| Q3 24 | 2.4% | 3.3% | ||
| Q2 24 | 2.6% | 3.2% | ||
| Q1 24 | 1.9% | 2.7% |
现金转化率MMSRVTY
| Q4 25 | -2.60× | 1.85× | ||
| Q3 25 | 8.63× | 2.97× | ||
| Q2 25 | -1.72× | 2.49× | ||
| Q1 25 | 0.44× | 3.03× | ||
| Q4 24 | -1.94× | 1.84× | ||
| Q3 24 | 2.26× | 1.57× | ||
| Q2 24 | 2.22× | 2.87× | ||
| Q1 24 | 1.62× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MMS
| Clinical Services | $523.7M | 39% |
| Cost Plus Contracts | $386.4M | 29% |
| Outside The United States | $143.2M | 11% |
| International Government Agencies | $141.0M | 10% |
| Technology Solutions | $74.8M | 6% |
| Employment And Other | $70.2M | 5% |
| Other Including Local Municipalities And Commercial Customers | $17.6M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
